{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-029069","form_type":"8-K","ticker":"SMTI","cik":"0000714256","company_name":"Sanara MedTech Inc.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.470708+00:00","generated_at":"2026-06-11T08:56:21.851724+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sanara MedTech clarifies Q2 sales per facility grew YoY but declined QoQ","bullets":["On Aug 15, 2023 earnings call, Sanara MedTech said sales per facility were growing; today's 8-K clarifies it was YoY, not QoQ.","Sequentially (Q2 2023 vs Q1 2023), sales per facility slightly declined.","Metric calculated as monthly Surgical Products sales divided by number of facilities with revenue; quarterly is average of monthly.","Surgical Products include CellerateRX, FORTIFY TRG, FORTIFY FLOWABLE, TEXAGEN, BiFORM, AMPLIFY, ALLOCYTE.","Correction filed under Regulation FD to avoid misleading investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-029069","json":"https://secwatch.observer/filing/0001493152-23-029069.json","markdown":"https://secwatch.observer/filing/0001493152-23-029069.md","text":"https://secwatch.observer/filing/0001493152-23-029069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/714256/000149315223029069/0001493152-23-029069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/714256/000149315223029069/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:56:21.851724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}